Stockscreener 앱 받기
44.24
0.20%
-0.09
시장 영업 전:
43.49
-0.75
-1.70%
전일 마감가:
$44.33
열려 있는:
$44.17
하루 거래량:
1.69M
Relative Volume:
0.52
시가총액:
$106.01B
수익:
$49.41B
순이익/손실:
$5.59B
주가수익비율:
18.53
EPS:
2.3875
순현금흐름:
$8.32B
1주 성능:
-1.29%
1개월 성능:
+3.66%
6개월 성능:
-4.28%
1년 성능:
-2.40%
1일 변동 폭
$44.02
$44.36
1주일 범위
$44.02
$45.23
52주 변동 폭
$40.89
$52.68
사노피 ADR Stock (SNY) Company Profile
Compare SNY vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
44.24 | 108.19B | 49.41B | 5.59B | 8.32B | 2.3875 |
LLY
Lilly Eli Co
|
1,149.36 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
275.23 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.46 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
150.33 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.99 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
사노피 ADR Stock (SNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-20 | 다운그레이드 | BNP Paribas Exane | Outperform → Neutral |
| 2026-02-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2026-01-27 | 개시 | Citigroup | Neutral |
| 2026-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2026-01-06 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-12-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-12-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-09-08 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-02 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-08-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
| 2025-03-21 | 개시 | Goldman | Neutral |
| 2025-01-30 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-07-26 | 재확인 | Argus | Buy |
| 2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 재개 | UBS | Buy |
| 2023-12-05 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-10-30 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-09-06 | 업그레이드 | Berenberg | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-28 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-03-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-12-13 | 재개 | Morgan Stanley | Overweight |
| 2022-08-12 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-08-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-09-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | 개시 | Deutsche Bank | Sell |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-03-17 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-03-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-02-11 | 개시 | SVB Leerink | Mkt Perform |
| 2020-01-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-09-20 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | 개시 | Bernstein | Outperform |
| 2019-08-14 | 업그레이드 | UBS | Neutral → Buy |
| 2018-12-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-11-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-09 | 개시 | Guggenheim | Neutral |
| 2018-09-10 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-03-23 | 업그레이드 | Liberum | Hold → Buy |
| 2018-01-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2017-12-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2017-08-30 | 업그레이드 | HSBC Securities | Reduce → Hold |
모두보기
사노피 ADR 주식(SNY)의 최신 뉴스
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight - GlobeNewswire Inc.
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Sanofi ADSADR Key Financial Ratios – Valuation, Profitability & More - Value Research
European ADRs Slipped In US Trading Late Thursday Morning - Finimize
Sanofi-ADR (NASDAQ:SNY): A Dividend Quality Candidate with Solid Profitability - ChartMill
Sanofi stock holds firm as workforce shake-up follows strong Q2 2026 - AD HOC NEWS
Sanofi stock steadies after strong Q2 2026 and upgraded guidance - Ad-hoc-news.de
Sanofi stock steadies as upgraded 2026 guidance follows strong Q2 momentum - AD HOC NEWS
European ADRs Drift Lower In US Trading - Finimize
Sanofi stock climbs as MenQuadfi approval and cuts reshape the story - Ad-hoc-news.de
Sanofi stock edges higher as MenQuadfi approval and workforce reshaping define mid-August story - Ad-hoc-news.de
Sanofi's New Leadership Faces Looming Patent Cliff - Morningstar
6 Undervalued Stocks That Crushed Earnings - Morningstar
Resilient Sanofi stock edges higher as Q2 2026 growth and R&D reshuffle shape outlook - Ad-hoc-news.de
Sanofi stock holds steady as India unit boosts profit and secures tax refund - Ad-hoc-news.de
Trump considers order on autism and vaccines: which stocks are most exposed? - Investing.com
Nurix earns $10m milestone as Sanofi starts STAT6 degrader trial - Investing.com Nigeria
ETFs Investing in Sanofi SA Sponsored ADR Stocks - TradingView
Key facts: Sanofi SA Sponsored ADR files H1 2026; halts three drugs - TradingView
What's behind Sanofi's latest 5.4% stock pullback? - tradersunion.com
European ADRs Jump In US Trading As Banks Lead - Finimize
Sanofi ADR earnings beat by $1.30, revenue topped estimates - Investing.com
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
SNY Stock Quote Price and Forecast - CNN
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings - Sahm
Ericsson Stock Slumps As ADR Underperformance Weighs On Traders - StocksToTrade
SANOFI-ADR (NASDAQ:SNY): A Decent Value Stock With Strong Fundamentals and an Undervalued Profile - ChartMill
Sanofi SA (HAM:SNW2) Stock Price, Trades & News - GuruFocus
NOK Stock Slides As ADR Weakness Puts Pressure On Bulls - StocksToTrade
As Biopharma Turns to China, ESG Risks and Geopolitics Remain in Focus - Morningstar
NOK Stock Slips Again As ADR Weakness Worries Traders - StocksToTrade
Sanofi stock slides as price lingers below the long-term average - Traders Union
Sanofi Reports Data From Nexviazyme Study, Says It Meets All Endpoints - Sahm
9 New 5-Star Stocks This Week - Morningstar
SNW2 Forecast — Price Target — Prediction for 2027 - TradingView
662283 Forecast — Price Target — Prediction for 2027 - TradingView
EU Launches Antitrust Probe Into Sanofi Over Allegedly Misleading Flu Vaccine Claims - Sahm
Sanofi faces EU probe, shares steady after Friday’s Reuters report - ad-hoc-news.de
Sanofi SA Sponsored ADR Actuals & Estimates (NASDAQ:SNY) - TradingView
Enterprise value to revenue forward of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView
Price to earnings forward of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView
Sanofi: Dupixent Risks Overstated, Valuation Disconnect Creates Opportunity (NASDAQ:SNY) - Seeking Alpha
Price to book forward of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView
Europe Approves Sanofi's Multiple Sclerosis Drug Despite FDA Rejection - Sahm
Sanofi analyst focus on Dupixent and pipeline, shares tracked against Big Pharma peers - AD HOC NEWS
사노피 ADR (SNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.25%
자본화:
|
볼륨(24시간):